Reports Q3 revenue ($600,000), consensus $5.89M. During Q3 SCYNEXIS recognized a non-cash gain of $7.5M. Cash, cash equivalents and investments totaled $105.2M on September 30, compared to $73.5M on December 31, 2022. “We faced unexpected challenges associated with the recent BREXAFEMME recall and the clinical hold placed on the MARIO trial this quarter,” said David Angulo, President and CEO of SCYNEXIS. “While options for resolution of these issues are being evaluated we continue making progress towards data analysis for recently completed clinical studies. Our solid cash position has allowed us to advance the development of our next generation triterpenoid antifungal ‘SCY-247’ and continue to seek to maximize shareholder value while avoiding the volatile capital markets.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SCYX:
- SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Scynexis files to sell 32.52M shares of common stock
- SCYX Earnings this Week: How Will it Perform?
- Scynexis presents new preclinical data on SCY-247
- SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)